
X
Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech roles
https://pharmaphorum.com/news/ex-roche-novartis-astrazeneca-leaders-appointed-to-biotech-roles/
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
Treatment promises cure by reactivating immune cells to kill latent HIV-infected cells.